Silva Fernández Lucía, Fernández Castro Mónica, Andreu Sánchez José Luis
Servicio de Reumatología. Hospital Universitario Puerta de Hierro. Madrid. España.
Reumatol Clin. 2007 Nov;3(6):262-9. doi: 10.1016/S1699-258X(07)73701-4. Epub 2008 Nov 13.
Glucocorticoids (GC) are a mainstay of the therapy in rheumatoid arthritis (RA). Currently, and despite their extensive use, the discussion about the benefits and adverse effects of low dose GC in the management of RA persists. In recent years, a number of clinical trials have attempted to establish the benefits of long-term GC use as a disease-modifying antirheumatic drug in RA, and to define their side effects. Results of these clinical trials provide solid evidence that low-dose GC can inhibit radiographic damage in early RA, and that side effects of GC, when used in that clinical framework, are limited to hyperglycaemia, cataracts, and transient weight gain.
糖皮质激素(GC)是类风湿关节炎(RA)治疗的主要药物。目前,尽管其广泛使用,但关于低剂量GC在RA治疗中的益处和不良反应的讨论仍在继续。近年来,一些临床试验试图确定长期使用GC作为RA改善病情抗风湿药的益处,并明确其副作用。这些临床试验的结果提供了确凿证据,表明低剂量GC可抑制早期RA的影像学损伤,并且在该临床背景下使用GC时,其副作用仅限于高血糖、白内障和短暂体重增加。